Question 1

What is SUTIMLIMAB-JOME used for?

Accepted Answer

SUTIMLIMAB-JOME (brand name Enjaymo) is a Other indicated for See full prescribing information.

Question 2

How does SUTIMLIMAB-JOME work?

Accepted Answer

SUTIMLIMAB-JOME works through the following mechanism: 12.1 Mechanism of Action Sutimlimab-jome is an immunoglobulin G (IgG), subclass 4 (IgG4) monoclonal antibody (mAb) that inhibits the classical complement pathway (CP) and specifically binds to complement protein component 1, s subcomponent (C1s), a serine protease which cleaves C4. Sutimlimab-jome does not inhibit the lectin and alternative pathways. Inhibition of the classical complement pathway at the level of C1s prevents deposition of complement opsonins on the surface of RBCs, resulting in inhibition of hemolysis in patients with CAD..

Question 3

What are the most common side effects of SUTIMLIMAB-JOME?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for SUTIMLIMAB-JOME. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is SUTIMLIMAB-JOME the same as Enjaymo?

Accepted Answer

Enjaymo is a brand name for SUTIMLIMAB-JOME. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

SUTIMLIMAB-JOME

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations